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Previously, andrographolide, which is the major diterpenoid of Andrographis
paniculata, was shown to have in vivo antitumour activity against human breast tumour
xenografts. In this study, among the four compounds isolated from A. paniculata,
andrographolide was the most potent compound with a mean ICso value of 8 IlM in
MCF-7 human breast cancer cells. Neoandrographolide showed a weak cytotoxic effect,
whereas 14-deoxy-ll,12-didehydroandrographolide and 14-deoxyandrographolide failed
to exhibit growth inhibitory effect at the highest tested concentration of 100 IlM. Owing
to this, andrographolide was considered as the lead compound in the discovery of potent
and selective anti tumour agents.
Using andrographolide isolated from A. paniculata as one of the starting materials, 3,19-
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benzylidene andrographolide and 3,19-alkylidene andrographolide derivatives were
synthesised by coupling of the two -OH groups present at C-3 and C-19 of
andrographolide with different benzaldehydes and alkyl aldehydes, respectively. In
addition, new derivatives were also synthesised by acetylation, oxidation, Heck and
esterolysis reactions. The structures of new derivatives of andrographolide derivatives
were confirmed by spectral analysis eH/J3C NMR, MS, FT-IR, UV).
Forty seven compounds including andrographolide were tested for antitumour activities
in MCF-7 and HCT-116 (colon) cancer cell lines. Using a 72 h MTT cell viability assay,
parameters of dose-response effects, GIso, TGI and LCso were determined. The
derivatives had submicromolar GIso values, except for 3,19-(4-
nitrobenzylidene)andrographolide (SRJS8), which showed the most potent activity with
a GIso value of 0.7 llM in MCF-7 cells. Only (Z)-2-[1-benzylamino-2-(5,5,6,8a-
tetramethyl-2-methylene-decahydro-naphthalen-1-yl)-ethyl]-4-hydroxy-but-2-enoic acid
benzylamide] (SRJ18), displayed a pronounced selectivity (approximately 8-fold)
towards HCT-116 cells at the GIso value compared with MCF-7 cells.
Out of the five compounds (3,19-isopropylideneandrographolide (SRJOl), 14-
acetylandrographolide (SRJ03), 3,19-(2-bromobenzylidene)-14-deoxy-11,12-didehydro
andrographolide (SRJOS), 3,19-(2-bromobenzylidene)andrographolide (SRJ09) and
3,19-(3,4-dimethoxybenzylidene)andrographolide (SRJ13)) tested against the 60
National Cancer Institute (NCI) of USA human cancer cell lines, only SRJ09 showed
some form of selectivity towards cancers of the colon, central nervous system, renal and
melanoma. The mechanism(s) of actions of the compounds were also studied by
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determining their effect in inducing cell cycle arrest and apoptosis. Andrographolide,
SRJOI and SRJ03 induced G1 and Gz/M arrest in MCF-7 cells, whereas 3,19-(4-
bromobenzylidene)andrographolide (SRJ08), SRJ09, 3,19-(3-bromobenzylidene)
andrographolide (SRJIO), 3,19-(3-chloro-4-fluorobenzylidene)andrographolide (SRJ23)
and 3,19-(2-fluorobenzylidene)andrographolide (SRJ27) induced only GI-phase arrest
in MCF-7 cells. SRJ09 down-regulated CDK4 (a G]-phase regulator) protein levels in
MCF-7 cells, which explains the G] -phase arrest by the compound. NCrs COMPARE
mechanistic analysis revealed that the compounds antitumour activities were not similar
to that of standard anticancer drugs with known mechanisms of action. Projection of
SRJ03 in the Self-Organising Maps (SOMs) analyses of NCr suggested that this
compound may be targeting cell cycle related phosphatases or kinases. However,
andrographolide, SRJOl, SRJOS, SRJ09 and SRJ13 did not project in the known
mechanism categories.
The mode(s) of cell death induced by SRJ09 and SRJ23, identified by fluorescence
microscopy and flow cytometry, was confirmed to be apoptosis in HCT-116 cells.
In conclusion, novel derivatives of andrographolide, especially SRJ09, SRJ18 and
SRJS8 are potential lead molecules for future antitumour studies to discover prospective
clinical candidates.
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Andrographolide merupakan diterpenoid utama tumbuhan Andrographis paniculata dan
kajian terdahulu menunjukkan andrographolide mempunyai aktiviti anti-tumor secara in
vivo terhadap xenograf tumor payudara manusia. Dalam kajian ini, andrographolide
merupakan sebatian yang paling poten diantara empat sebatian daripada A. paniculata,
dengan nilai min ICso 8 11M dalam sel kanser payudara manusia MCF-7.
Neoandrographolide mempamerkan kesan sitotoksik yang lemah, manakala I4-deoxy-
II,I2-didehydroandrographolide dan I4-deoxyandrographolide gagal menunjukkan
kesan perencatan tumbesaran apabila diuji pada kepekatan tertinggi iaitu 100 11M.
Justeru itu, andrographolide telah dipilih sebagai sebatian asas dalam usaha
menghasilkan agen antitumor yang poten dan selektif berasaskan struktur rangka
andrographolide.
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Dengan menggunakan andrographolide yang diasingkan daripada A. paniculata sebagai
bahan asas, 3,19-benzilidene andrographolide dan 3,19-alkilidene andrographolide
disintesis dengan mengkupelkan dua kumpulan -OH pada kedudukan C-3 dan C-19
andrographolide masing-masing dengan benzaldehid dan alkil aldehid. Selain itu,
terbitan andrographolide juga disintesis melalui proses asetilasi, oksidasi, tindakbalas
Heck dan esterolisis. Struktur bagi terbitan baru andrographolide disahkan dengan
menggunakan analisis spektral eR/13C NMR, MS, FT-IR, UV).
Kesemua sebatian termasuk andrographolide diuji untuk menentukan antitumor terhadap
kultur kanser payudara, MCF-7 dan kanser kolon, RCT-116. Dengan menggunakan asai
viabiliti sel MTT selama 72 jam, nilai GIso, TGI dan LCso ditentukan. Kesemua sebatian
terbitan menunjukkan nilai GIso submikromolar terhadap kedua-dua jenis sel
terutamanya 3,19-(4-nitrobenzylidene)andrographolide (SRJ58), yang menunjukkan
aktiviti paling poten dengan nilai GIso pada 0.7 IlM. Antara sebatian-sebatian tersebut, 8-
kali ganda (Z)-2-[I-Benzylamino-2-(5,5,6,8a-tetramethyl-2-methylene-decahydro-
naphthalen-l-yl)-ethyl]-4-hydroxy-but-2-enoic acid benzylamide (SRJ18),
menunjukkan selektiviti terhadap sel RCT-116 dengan katara pada nilai GIso berbanding
sel MCF-7.
Daripada lima sebatian (3,19-isopropylideneandrographolide (SRJOl), 14-
acetylandrographolide (SRJ03), 3,19-(2-bromobenzylidene)-14-deoxy-l1,12-didehydro
andrographolide (SRJ05), 3,19-(2-bromobenzylidene)andrographolide (SRJ09) and
3,19-(3,4-dimethoxybenzylidene)andrographolide (SRJ13)) yang telah diuji ke atas 60
jenis sel kanser oleh National Cancer Institute (NCI), USA, hanya SRJ09 menunjukkan
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selektiviti terhadap kanser sistem saraf pusat dan melanoma.
Andrographolide, SRJOI dan SRJ03 didapati mengaruh perencatan fasa G1 dan G2/M
pada sel MCF-7, manakala 3,19-(4-bromobenzylidene)andrographolide (SRJ08),
SRJ09, 3,19-(3-bromobenzylidene) andrographolide (SRJIO), 3,19-(3-chloro-4-
fluorobenzylidene)andrographolide (SRJ23) and 3,19-(2-fluorobenzylidene)-
andrographolide (SRJ27) hanya m erencatkan fasa G JP ada s el M CF-7. Kesan S RJ09
terhadap (oerangsangan hitaran regulaton cyclin) yang bergantung terhadap kinase 4
(CDK4) telah ditentukan melalui analisis Western blot. SRJ09 merencatkan tahap
CDK4 pada sel MCF-7 setelah dirawat selama 72 jam. Analisis NCr COMPARE
menunjukkan mekanisme aktiviti sebatian-sebatian ini, tidak sama seperti yang ada pada
dadah antikanser yang diketahui. Projeksi SRJ03 dalam analisis 'Self-Organising Maps'
(SOMs) mencadangkan mekanisma tindakannya berkemungkinan bersasar ke atas enzim
fosfatase atau kinase. Walau bagaimanapun, andrographolide, SRJOl, SRJ05, SRJ09
dan SRJ13 tidak dipamerkan dalam kategori mekanisma yang diketahui.
Mekanisma kematian sel yang diaruh oleh agen baru ini dikenalpasti melalui
pemerhatian mikroskop pendaflor dan 'sitometri aliran'. Daripada kedua-dua kaedah ini,
apoptosis dikenal pasti sebagai mekanisma utama kematian sel HCT-116 yang dirawat
dengan SRJ09 dan SRJ23.
Secara kesimpulan, sebahagian sebatian terbitan andrographolide, terutamanya SRJ09,
SRJ18 dan SRJ58 menpunyai potensi sebagai komponen utama kajian antitumor untuk
menemui calon klinikal yang bekesan di masa hadapan.
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CHAPTER 1
LITERATURE REVIEW
1.1 Introduction
The use of plants as medicines goes back to early man. Certainly the great
civilisations of t he a ncient Indians, Chinese, a nd North Africans provided written
evidence of man's ingenuity in utilising plants for the treatment of a wide variety of
diseases. In ancient Greece, scholars classified plants and gave descriptions of them
thus aiding the identification process. It was not until the 19th century that man began
to isolate the active principles of medicinal plants and one particular landmark was
the discovery of quinine from Cinchona bark by the French scientists Caventou and
Pelletier. Such discoveries led to an interest in plants from the New World and
expeditions scoured the almost impenetrable jungles and forests in the quest for new
medicines (reviewed by Phillipson, 2001). Despite major scientific and technological
progress in combinatorial chemistry, drugs derived from natural products still make
an enormous contribution to drug discovery today (reviewed by Phillipson, 2001).
Nature is an attractive source of new therapeutic candidate compounds and has a
tremendous chemical diversity found in millions of species of plants, animals, marine
organisms and microorganisms. The development of novel agents from natural
sources presents obstacles t hat are not usually met when 0 ne deals with synthetic
compounds. For instance, there may be difficulties in accessing the source of the
samples, obtaining appropriate amounts of the sample, identification and isolation of
the active compound in the sample, and problems in synthesising the necessary
amounts of the compound of interest (Rocha et al., 2001).
2There are about 500,000 species of plants growing on the earth and it is estimated
that at least 5000 different chemical compounds of secondary metabolites are present
in a single species of plant (reviewed by Verpoorte, 1 998). It is apparent that the
secondary metabolites of plant origin constitute a tremendous resource for exploring
useful d rugs. I n plants, the primary metabolites, including proteins, lipids, nucleic
acids, enzymes, and coenzymes, etc., come from the metabolism of carbohydrates
with the incorporation of nitrogen and mineral elements. By utilising primary
metabolites and numerous infinite molecules, plants synthesise the secondary
metabolites for the purpose of survival and well being. Taxonomically related plants
generally produce chemically similar secondary metabolites and, therefore, may have
similar phannacological effects. Natural products exhibiting antitumour activity
continue to be the subject of extensive research aimed at the development of drugs
for the treatment of different human tumours.
In the early 1950s, a research program screening for antitumour drugs of plant origin
was initiated mainly by the National Cancer Institute (NCI) in the USA. Large-scale
screening procedures were made available, plant materials were produced, and crude
extracts were put through preliminary screening. Basic phannacological and
toxicological studies in animals ensued, and finally, a number of promising
compounds were selected for chemical studies, with the ultimate goal of finding the
active antitumour drugs from plants. This program represented a combined effort
mobilising many biomedical research organisations in the government and in
medical, phannaceutical, and chemical institutes and industries. T he achievements
during the past few decades have been very rewarding (reviewed by Cragg et al.,
1999).
